Immuron (FRA:ANWA) Short Percentage of Float


FRA:ANWA Immuron Ltd FRA:ANWA
56 GF Score
Price €0.93
GF Value €5.48
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Immuron Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:ANWA vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Immuron's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuron Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Immuron's Short Percentage of Float falls into.


FRA:ANWA
56GF Score
Immuron Ltd FRA:ANWA
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immuron (FRA:ANWA) Overvalued in 2026?

Based on GuruFocus' analysis, Immuron stock appears to be undervalued. The current stock price of €0.93 is trading 83% below its estimated GF Value™ of €5.48. GuruFocus considers Immuron to be Possible Value Trap.

Key valuation signals for FRA:ANWA:

  • Short Percentage of Float:
  • GF Value™: €5.48 vs. price of €0.93 (83% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:ANWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immuron Business Description

Address 25-37, Chapman Street, Unit 10, Blackburn, Melbourne, VIC, AUS, 3130
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
56GF Score

Get the complete analysis for FRA:ANWA

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.93
Price
€5.48
GF Value